Evidence map›Paper›PMID 41527826›Full record

Trial reportStroke2026

Lp-PLA2 Activity and Genotype-Guided Dual Antiplatelet Therapy in Minor Stroke or Transient Ischemic Attack.

Jinxi Lin, Hongyu Zhou, Yubo Wang, Aoming Jin, Shangzhi Li, Ling Zhang, Xia Meng, Xuewei Xie, Jing Jing, Yong Jiang and 6 more

Registry-linked trialAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Stroke, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04078737 (Clopidogrel With Aspirin in High-risk Patients With Acute Non-disabling Cerebrovascular Events II), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04078737 phase3completednot on this map

Clopidogrel With Aspirin in High-risk Patients With Acute Non-disabling Cerebrovascular Events II

TypeinterventionalSponsorBeijing Tiantan HospitalRan2019 to 2021Enrolled6,412ConditionsStroke, Transient Ischemic AttackArmsTicagrelor and Aspirin, Clopidogrel and Aspirin
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Jinxi Lin *Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (J.L., H.Z., Yubo Wang, A.J., S.L., L.Z., X.M., X.X., J.J., Y.J., Yilong Wang, X.Z., H.L., Z.L., Yongjun Wang).
Hongyu Zhou *Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (J.L., H.Z., Yubo Wang, A.J., S.L., L.Z., X.M., X.X., J.J., Y.J., Yilong Wang, X.Z., H.L., Z.L., Yongjun Wang).ORCID 0000-0002-9130-889X
Yubo Wang *Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (J.L., H.Z., Yubo Wang, A.J., S.L., L.Z., X.M., X.X., J.J., Y.J., Yilong Wang, X.Z., H.L., Z.L., Yongjun Wang).ORCID 0000-0001-8248-8959
Aoming JinDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (J.L., H.Z., Yubo Wang, A.J., S.L., L.Z., X.M., X.X., J.J., Y.J., Yilong Wang, X.Z., H.L., Z.L., Yongjun Wang).ORCID 0000-0002-7221-5444
Shangzhi LiDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (J.L., H.Z., Yubo Wang, A.J., S.L., L.Z., X.M., X.X., J.J., Y.J., Yilong Wang, X.Z., H.L., Z.L., Yongjun Wang).
Ling ZhangDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (J.L., H.Z., Yubo Wang, A.J., S.L., L.Z., X.M., X.X., J.J., Y.J., Yilong Wang, X.Z., H.L., Z.L., Yongjun Wang).
Xia MengDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (J.L., H.Z., Yubo Wang, A.J., S.L., L.Z., X.M., X.X., J.J., Y.J., Yilong Wang, X.Z., H.L., Z.L., Yongjun Wang).
Xuewei XieDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (J.L., H.Z., Yubo Wang, A.J., S.L., L.Z., X.M., X.X., J.J., Y.J., Yilong Wang, X.Z., H.L., Z.L., Yongjun Wang).ORCID 0000-0001-8154-1957
Jing JingDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (J.L., H.Z., Yubo Wang, A.J., S.L., L.Z., X.M., X.X., J.J., Y.J., Yilong Wang, X.Z., H.L., Z.L., Yongjun Wang).ORCID 0000-0001-9822-5758
Yong JiangDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (J.L., H.Z., Yubo Wang, A.J., S.L., L.Z., X.M., X.X., J.J., Y.J., Yilong Wang, X.Z., H.L., Z.L., Yongjun Wang).ORCID 0000-0001-7700-6054
Yilong WangDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (J.L., H.Z., Yubo Wang, A.J., S.L., L.Z., X.M., X.X., J.J., Y.J., Yilong Wang, X.Z., H.L., Z.L., Yongjun Wang).ORCID 0000-0003-2725-2788
Xingquan ZhaoDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (J.L., H.Z., Yubo Wang, A.J., S.L., L.Z., X.M., X.X., J.J., Y.J., Yilong Wang, X.Z., H.L., Z.L., Yongjun Wang).ORCID 0000-0001-8345-5147
Hao LiDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (J.L., H.Z., Yubo Wang, A.J., S.L., L.Z., X.M., X.X., J.J., Y.J., Yilong Wang, X.Z., H.L., Z.L., Yongjun Wang).
Zixiao LiDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (J.L., H.Z., Yubo Wang, A.J., S.L., L.Z., X.M., X.X., J.J., Y.J., Yilong Wang, X.Z., H.L., Z.L., Yongjun Wang).ORCID 0000-0002-4713-5418
Yongjun WangDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (J.L., H.Z., Yubo Wang, A.J., S.L., L.Z., X.M., X.X., J.J., Y.J., Yilong Wang, X.Z., H.L., Z.L., Yongjun Wang).ORCID 0000-0002-9976-2341
CHANCE-2 Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLp-PLA2 (lipoprotein-associated phospholipase A2) is a sensitive biomarker of vascular inflammation and atherosclerosis. This study evaluated the influence of Lp-PLA2 activity on the efficacy and safety of ticagrelor-aspirin versus clopidogrel-aspirin among patients with minor stroke or transient ischemic attack carrying

methodsThe CHANCE-2 trial (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events-II) randomized 6412 patients with minor stroke or transient ischemic attack carrying

resultsA total of 5919 patients were included (mean age, 64.4 years; 33.9% female). Among patients with low Lp-PLA2 activity, ticagrelor-aspirin reduced the 90-day risk of recurrent stroke compared with clopidogrel-aspirin (5.4% versus 7.4%; adjusted hazard ratio, 0.72 [95% CI, 0.54-0.97]). In patients with high Lp-PLA2 activity, no significant difference was observed (6.9% versus 8.2%; adjusted hazard ratio, 0.84 [95% CI, 0.65-1.09]). The

conclusionsIn patients with minor stroke or transient ischemic attack carrying REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04078737.

Indexed as

1-Alkyl-2-acetylglycerophosphocholine EsteraseAspirinClopidogrelDual Anti-Platelet TherapyIschemic Attack, TransientPlatelet Aggregation InhibitorsStrokeAgedCytochrome P-450 CYP2C19Drug Therapy, CombinationFemaleGenotypeHumansMaleMiddle AgedTicagrelor1-Alkyl-2-acetylglycerophosphocholine EsteraseAspirinClopidogrelCYP2C19 protein, humanCytochrome P-450 CYP2C19Platelet Aggregation InhibitorsTicagreloraspirinatherosclerosisclopidogrelinflammationticagrelor

Identifiers

PMID41527826
PMCPMC13003939

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.